5 results about "IGF-Binding Proteins" patented technology

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

The present disclosure provides composition for use in treating disorders, such as eye disorders (e.g., disorders affecting Meibomian glands). Composition(s) for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGF1R. Such compositions may evade IGF binding proteins. Related methods, kits, and pharmaceutical compositions are also disclosed.

The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and / or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500 μg / Kg / day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and / or protection from circulatory collapse.

The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.

The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and / or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500µg / Kg / day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and / or protection from circulatory collapse.